




# Sequence-defined oligomers for intracellular delivery of nucleic acids, drugs, proteins




**CeNS**

Center for NanoScience | LMU

al and artificial oligo-amino acids

22 - 09 - 2015



## Bioresponsive carriers

- **multifunctional and precise**


## Strategy: learn from viruses and natural evolution

### > Chemical evolution:


- identify **chemical motifs** for delivery
- assemble chemical **motifs** into **defined sequences**
- shuffle into various **topologies**
- optimize **nanoparticle assembly**

Identify chemical motifs for delivery:

# pH-responsive diamino ethane motif



PEI branched or linear  
(Boussif et al, JP Behr 1995)  
PEI is nondegradable & toxic




*Other delivery motifs:*

His, KHH; C; CXC; OleA<sub>2</sub>, LinA<sub>2</sub>; Y<sub>3</sub>; INF7; TAT; receptor ligands

Ulrich Lächelt *Chemical Reviews* 2015

Nucleic Acid Therapeutics Using Polyplexes – A Journey of 50 Years (and Beyond).

# Solid phase supported polymer synthesis




Compare:

Laura Hartmann, Hans Börner

Sequence-defined precision polymers

**'Artificial oligoamino acids'**  
**(diaminoethane motifs)**





> 900 sequences;  
different topologies  
excellent biocompatibility



David Schaffert

*Org Lett* 2011, *Angewandte Chemie* 2011, *Bioconjug Chem* 2012

# Correlation of polymer size with gene transfer and cytotoxicity




LPEI 22kDa: approx 500 ( $\pm 200$ ) nitrogens




Stp<sub>30</sub>: 91 amine nitrogens (150 nitrogens)



## Polymer cytotoxicity





# Diaminoethane and histidine motif: Fine-tuning of proton sponges




EC: extracellular  
 EE: early endosomes  
 LE: late endosomes  
 L: lysosomes  
 NA: nucleic acid

# Fine-tuning of proton sponges:


## Protonation in endosomal pH range




	Buffer capacity (pH 5-7.4)
610 / A-(GTT-A) <sub>3</sub>	31.7 ± 1.7%
611 / H-(GTT-H) <sub>3</sub>	33.6 ± 0.5%
612 / A-(STP-A) <sub>3</sub>	14.7 ± 0.6%
613 / H-(STP-H) <sub>3</sub>	22.4 ± 0.9%
614 / A-(SPH-A) <sub>3</sub>	23.6 ± 2.1%
615 / H-(SPH-H) <sub>3</sub>	27.9 ± 1.3%



(GTT-H)<sub>m</sub>  
(n = m \* 2)




(STP-H)<sub>m</sub>  
(n = m \* 3)




(SPH-H)<sub>m</sub>  
(n = m \* 4)


# Four-arms containing histidine: Systemic delivery in sc N2A tumor model



pDNA polyplexes N/P 12



**His-Sph 4-arm: 30-fold enhanced gene transfer into tumor**





# Targeted PEG-shielded polyplexes


Martin *Org Biomol Chem* 2012

Kos *J Pharm Sci* 2015

Kos *Nanoscale* 2014

An *Small* 2015

Zhang *J Gene Med* 2015




Lee *submitted* 2015

Lächelt *Mol Pharm* 2014

Dohmen *ACS Nano* 2012




# Targeted PEG-shielded polyplexes: Histidines enhance endosomal escape



Ligand-PEG-STP-**Ala/His**

PEG: 24 EO units

STP arms: 24 EI units



Bräuchle lab: polyplexes plus calcein (3.5 h, SD-CFLM)

Ulrich Lächelt *Nanomedicine NBM* 2014

Ellen Broda *JCR* 2015: cell binding under flow: B6 not via TfR ! cMBP2 binds via c-Met

# *New targeting ligand:* c-Met Binding Peptide (cMBP2)


## c-Met / Hepatocyte growth factor receptor

Tyrosine kinase


Proliferation & progression of malignancies

High expression in late stage and metastases of prostate cancer

c-Met binding peptides (cMBP1, cMBP2)




Petra Kos, Uli Lächelt, Annika Herrmann, Dongsheng He *Nanoscale* 2015




L. Appleman, *JCO* 2011;29: 4837

# Cellular internalization (c-Met targeting)

DU-145  
prostate ca




HUH-7  
hepatocellular ca



Ala-PEG-STP

cMBP2-PEG-STP

Ala-PEG-STP-His (dotted) cMBP2-PEG-STP-His (dotted)





# c-Met binding peptide for tumor targeting

## Systemic delivery in HUH7 tumor model


*In vitro* and intratumoral: nice targeting, His effect

*Systemic*: moderate activity, no targeting effect




PEG segments

shield surface, but interfere with  
DNA - DNA **compaction**






hexagonal  
columnar phase  
Derouchey, Netz, Rädler  
EPJE 2005



# c-Met binding peptide for tumor targeting



## Systemic delivery in HUH7 tumor model




# c-Met binding peptide for tumor targeting

## Systemic delivery in HUH7 tumor model


N/P 12; mixture 7:3 ratio



cMBP2 vs Ala




Mix: cMBP2 vs Ala




**cMBP plus His: 50-fold enhanced gene transfer**

# *OleA2 – NP stabilizing and lytic motif :* EG5 (Eglin-5, KSP) knockdown by siRNA




EG5 siRNA / T-shape lipo-oligomer **49**  
(polyplexes stable for weeks at RT)

## Mitotic aster formation



## Tumor growth reduction




N2A tumors, intratumoral administrations







# Polyplex stabilizing motifs: Tyrosine trimer (Y3) and CXC



Free Cy7-siRNA




Y<sub>3</sub>-Stp<sub>2</sub>-[(OleA)<sub>2</sub>-K]K-Stp<sub>2</sub>-Y<sub>3</sub>

Christina Troiber  
Biomaterials 2013





intravenous administration correlates well with *ex vivo*  
Fluorescence Correlation Spectroscopy in 90% serum



Philipp Klein et al *JCR* 2015 (JC Leroux, M. Gauthier ETHZ)


## Folate for targeting:

## Multifunctional siRNA polyplexes



**Cys for polyplex stability**

**FoIA for cellular uptake**





**(influenza peptide) for endosomal escape**


Diameter (PEG-24) **5.8 (±0.2) nm**

siRNA uncomplexed 4.2 (±0.2) nm


Zeta potential **0.0 (±2.4) mV**



# Target gene silencing



# Folate dependent gene silencing in tumor




Intratumoral Cy7-siRNA Polyplexes



Aster formation only with siEG5-INF7/356






# Angiopep 2 for targeting: Effective glioma-targeted siBAG3 delivery



## U87 *in vitro*







## Glioma *in vivo*








# DHFR inhibition T

ε MTX oligomers)





# Cell death by MTX / poly(I:C) nanoplexes








$n \uparrow \Rightarrow$  DHFR  $\downarrow$   
 Ligand Tox.  $\uparrow$   
 Poly(I:C) Tox.  $\uparrow$

Poly(I:C): double stranded RNA, cytotoxic after delivery into cytosol

Shir et al 2006; Schaffert et al 2011






# Gene silencing and cell death by 4E-MTX-Stp / siEG5 nanoplexes



188 no targeting ligand  
 356: Folate  
 640: 4E-MTX



# Cures by 4E-MTX-Stp / siEG5 nanoplexes






# Intracellular protein delivery by sequence-defined carriers



Kevin Maier, Irene Martin, Xiaowen Liu, Peng Zhang


# Three-arm shuttle for protein delivery

Reducible covalent disulfide linker



# Three-arm shuttle for protein delivery

## Acid-labile traceless click linker





## *Pharmaceutical Biotechnology (Ernst Wagner)*

Christian Dohmen  
Daniel Edinger  
Thomas Fröhlich  
Dongsheng He  
Annika Herrmann  
Eva Kessel  
Raphaela Kläger  
Melinda Kiss  
Petra Kos  
Ulrich Lächelt  
Dian-Jang Lee  
Xiaowen Liu  
Kevin Maier  
Irene Martin  
Katharina Müller  
Wolfgang Rödl  
David Schaffert  
Claudia Scholz  
Laura Schreiner  
Christina Troiber  
Valentin Wittmann  
Can Yang Zhang  
Peng Zhang  
Wei Zhang



### *LMU*

Thomas Bein  
Christoph Bräuchle  
Markus Döblinger  
Don Lamb  
Joachim Rädler  
Angelika Vollmar  
Wolfgang Friess  
Gerhard Winter  
Ahmed Besheer

### *Axolabs Kulmbach*

Philipp Hadwiger  
Hans-Peter Vornlocher

### *MPI Colloids Interfaces*

Felix Wojcik  
Laura Hartmann

### *Fudan U*

Rongqin Huang  
Chen Jiang  
Weiyue Lu  
Min Liu

### *Jerusalem U*

Alex Levitzki  
Alexei Shir

### *NERBC, Sichuan U*

Zhongwei Gu  
Yu Nie

### *COMPACT*

EC IMI network